{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8431","value":"0.188"},{"groupId":"OG001","spread":"0.4691","value":"0.067"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Blood samples were collected for local clinical laboratory assessment of lymphocyte count.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received trilaciclib 200 mg/m\\^2 administered intravenously (IV) once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 1: Cohort 1 Trilaciclib 200 mg/m^2"},{"description":"Participants received trilaciclib 240 mg/m\\^2 administered IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG001","title":"Part 1: Cohort 2 Trilaciclib 240mg/m^2"}],"paramType":"MEAN","populationDescription":"The FAS included all randomized patients who received at least 1 dose of study drug (etoposide, carboplatin, or trilaciclib). Analyses using the FAS were conducted on the basis of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6","title":"Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 1","type":"SECONDARY","unitOfMeasure":"x 10^9 cells/L"}